🇺🇸 FDA
Pipeline program

Autologous (self) mononuclear cells derived from umbilical cord blood

18-004753

Phase 2 mab active

Quick answer

Autologous (self) mononuclear cells derived from umbilical cord blood for Hypoplastic Left Heart Syndrome is a Phase 2 program (mab) at Regen BioPharma Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
Regen BioPharma Inc
Indication
Hypoplastic Left Heart Syndrome
Phase
Phase 2
Modality
mab
Status
active

Clinical trials